Literature DB >> 30026621

Long-term clinical control of feline pancreatic carcinoma with toceranib phosphate.

Andrea M Dedeaux1, Ingeborg M Langohr1, Bonnie B Boudreaux1.   

Abstract

An 11-year-old, spayed female, domestic shorthair cat was presented with a non-resectable abdominal mass diagnosed as carcinomatosis of pancreatic origin. Treatment with toceranib phosphate was started. Abdominal ultrasound approximately 1 year after diagnosis revealed progressive disease. The cat was humanely euthanized approximately 792 days after initial presentation due to progressive clinical signs.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30026621      PMCID： PMC6005131     

Source DB:  PubMed          Journal:  Can Vet J        ISSN： 0008-5286            Impact factor:   1.008


  20 in total

1.  Exocrine pancreatic neoplasia in the cat: a case series.

Authors:  Rebecca L Seaman
Journal:  J Am Anim Hosp Assoc       Date:  2004 May-Jun       Impact factor: 1.023

2.  Expression of VEGFR and PDGFR-α/-β in 187 canine nasal carcinomas.

Authors:  I Gramer; D Killick; T Scase; D Chandry; M Marrington; L Blackwood
Journal:  Vet Comp Oncol       Date:  2016-06-09       Impact factor: 2.613

3.  Veterinary cooperative oncology group - common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1.

Authors: 
Journal:  Vet Comp Oncol       Date:  2016-12       Impact factor: 2.613

4.  Retrospective evaluation of toceranib phosphate (Palladia) in cats with oral squamous cell carcinoma.

Authors:  Valerie Wiles; Ann Hohenhaus; Kenneth Lamb; Bushra Zaidi; Maria Camps-Palau; Nicole Leibman
Journal:  J Feline Med Surg       Date:  2016-07-09       Impact factor: 2.015

5.  Coordinate expression of cytokeratins 7 and 20 in feline and canine carcinomas.

Authors:  A Espinosa de los Monteros; A Fernández; M Y Millán; F Rodríguez; P Herráez; J Martín de las Mulas
Journal:  Vet Pathol       Date:  1999-05       Impact factor: 2.221

6.  Preliminary evidence for biologic activity of toceranib phosphate (Palladia(®)) in solid tumours.

Authors:  C London; T Mathie; N Stingle; C Clifford; S Haney; M K Klein; L Beaver; K Vickery; D M Vail; B Hershey; S Ettinger; A Vaughan; F Alvarez; L Hillman; M Kiselow; D Thamm; M L Higginbotham; M Gauthier; E Krick; B Phillips; T Ladue; P Jones; J Bryan; V Gill; A Novasad; L Fulton; J Carreras; C McNeill; C Henry; S Gillings
Journal:  Vet Comp Oncol       Date:  2011-06-01       Impact factor: 2.613

7.  Response to insulin treatment and survival in 104 cats with diabetes mellitus (1985-1995).

Authors:  M M Goossens; R W Nelson; E C Feldman; S M Griffey
Journal:  J Vet Intern Med       Date:  1998 Jan-Feb       Impact factor: 3.333

8.  Tolerability of toceranib phosphate (Palladia) when used in conjunction with other therapies in 35 cats with feline oral squamous cell carcinoma: 2009-2013.

Authors:  Gina A Olmsted; John Farrelly; Gerald S Post; Jaclyn Smith
Journal:  J Feline Med Surg       Date:  2016-03-07       Impact factor: 2.015

9.  Evaluation of expression and function of vascular endothelial growth factor receptor 2, platelet derived growth factor receptors-alpha and -beta, KIT, and RET in canine apocrine gland anal sac adenocarcinoma and thyroid carcinoma.

Authors:  Bridget K Urie; Duncan S Russell; William C Kisseberth; Cheryl A London
Journal:  BMC Vet Res       Date:  2012-05-25       Impact factor: 2.741

10.  Immunohistochemical expression of potential therapeutic targets in canine thyroid carcinoma.

Authors:  M Campos; R Ducatelle; H S Kooistra; G Rutteman; L Duchateau; I Polis; S Daminet
Journal:  J Vet Intern Med       Date:  2014-02-24       Impact factor: 3.333
View more
  1 in total

1.  Long-term survival in a cat with pancreatic adenocarcinoma treated with surgical resection and toceranib phosphate.

Authors:  Johanna E Todd; Sandra M Nguyen
Journal:  JFMS Open Rep       Date:  2020-06-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.